Heart Transplant Surgery — Cost, Top Hospitals & Success Rates | MyMedicPlus

Heart transplantation is a life-saving surgical procedure in which a diseased, failing heart is replaced with a healthy donor heart from a brain-dead or circulatory-death donor. It represents the gold-standard treatment for end-stage heart failure when all other medical and surgical therapies have been exhausted. The operation is performed under general anaesthesia with cardiopulmonary bypass, which temporarily takes over the pumping function of the heart and lungs while the diseased organ is excised and the donor heart is implanted.

Clinically, the procedure involves removing the recipient's failing heart while preserving a posterior cuff of the left atrium containing the pulmonary veins. The donor heart is then sutured in position using the bicaval technique — connecting the donor superior and inferior vena cavae directly to the recipient's own — which reduces tricuspid regurgitation and sinus node dysfunction compared to the older biatrial anastomosis method. Total operative time ranges from four to eight hours depending on complexity, prior cardiac surgeries, and the need for concomitant procedures.

Following implantation, the patient is transferred to a specialist cardiac intensive care unit for haemodynamic monitoring, early immunosuppression initiation, and recovery from bypass. The typical hospital stay after an uncomplicated transplant is ten to twenty-one days, after which lifelong immunosuppressive therapy — usually a combination of a calcineurin inhibitor (tacrolimus or ciclosporin), a cell-cycle inhibitor (mycophenolate mofetil), and corticosteroids — is required to prevent rejection of the donor organ.

Heart transplantation is indicated for patients with end-stage heart failure — defined as NYHA Class III–IV symptoms despite optimal medical and device therapy — who have a poor prognosis and no other viable surgical options. The most common underlying diagnoses leading to transplant are dilated cardiomyopathy (both ischaemic and non-ischaemic) and ischaemic heart disease with severely reduced left ventricular ejection fraction (typically below 25%).

Other conditions treated include hypertrophic cardiomyopathy refractory to septal reduction therapy, restrictive cardiomyopathies such as cardiac amyloidosis and sarcoidosis, severe valvular heart disease not amenable to repair or replacement, congenital heart disease with advanced ventricular dysfunction, and cardiac tumours not resectable by conventional surgery. In selected paediatric patients, transplant is also performed for complex congenital abnormalities where staged palliation has failed. Life expectancy on optimal medical therapy alone for these end-stage conditions is typically less than one year.

Ideal candidates are patients aged generally below 70 years (though physiological rather than chronological age guides the decision) with end-stage heart failure on maximal tolerated medication including ACE inhibitors or sacubitril/valsartan, beta-blockers, mineralocorticoid antagonists, and SGLT2 inhibitors. Candidates should have no other viable surgical option, acceptable renal function (GFR above 30 mL/min unless combined heart-kidney transplant is planned), absence of active malignancy, no active infection, acceptable nutritional status, and demonstrated psychosocial stability and compliance. A cardiopulmonary exercise test showing peak VO2 below 14 mL/kg/min (or below 50% predicted) is a key criterion; LVAD bridge-to-transplant may be used to stabilise higher-risk candidates awaiting a suitable donor.

Absolute contraindications include severe fixed pulmonary hypertension with pulmonary vascular resistance above 5 Wood units unresponsive to vasodilator challenge (which would lead to right heart failure of the donor heart), active or recent malignancy, severe irreversible renal or hepatic dysfunction (unless combined transplant is planned), active systemic infection, morbid obesity (BMI above 35 kg/m²), severe peripheral vascular disease, active substance abuse, and demonstrated non-compliance with medical therapy. Relative contraindications include advanced age, diabetes with end-organ damage, and active psychiatric disorders.

Orthotopic heart transplantation — in which the recipient's heart is completely removed and replaced with the donor heart in the same anatomical position — is the standard procedure performed in over 95% of cases. The bicaval biatrial technique is now preferred at most high-volume centres as it preserves sinus node function and reduces the rate of atrial arrhythmias. Heterotopic transplantation, where the donor heart is placed in parallel with the native heart in the right thoracic cavity, is rarely performed and largely reserved for cases of severe fixed pulmonary hypertension where the donor heart alone cannot manage the elevated afterload.

For patients who deteriorate while awaiting a donor organ, mechanical circulatory support with a left ventricular assist device (LVAD) is used as a bridge to transplantation. Modern continuous-flow LVADs (HeartMate 3, HVAD) significantly improve survival to transplant. In some centres, total artificial hearts (SynCardia) are used as a bridge in patients with biventricular failure. Ex-vivo heart perfusion systems such as the Transmediastinal Heart (OCS Heart) now allow donation-after-circulatory-death (DCD) hearts to be used, significantly expanding the donor pool — a major advance in transplant medicine over the past decade. Donation after circulatory death (DCD) hearts, reanimated using ex vivo normothermic machine perfusion (Organ Care System, TransMedics), have significantly expanded the donor pool — a major advance in transplant medicine over the past decade. Desensitisation protocols for highly sensitised recipients using plasmapheresis and rituximab have enabled previously impossible matches.

Heart transplantation provides dramatic improvement in survival and quality of life for appropriately selected patients with end-stage heart failure. According to the International Society for Heart and Lung Transplantation (ISHLT) registry, median survival after adult heart transplantation is approximately 12–13 years, with a one-year survival of around 85% and a five-year survival of approximately 75%. Patients who survive the first year can expect a median conditional survival of approximately 14 years. Importantly, over 90% of survivors at one year report no functional limitation, allowing return to near-normal activity levels, including work and exercise.

Long-term benefits include elimination of the profound fatigue, breathlessness, and fluid retention associated with end-stage heart failure, reduction or cessation of multiple heart failure medications, and restoration of meaningful quality of life. In younger patients, successful transplantation can provide decades of additional life. Advances in immunosuppression, surgical technique, and donor heart preservation have steadily improved outcomes over the past two decades. Paediatric recipients show particularly encouraging long-term results at experienced congenital and paediatric transplant centres.

Primary graft dysfunction — failure of the donor heart to function adequately immediately after transplantation — occurs in approximately 5–10% of cases and is the leading cause of early post-transplant mortality. Right heart failure of the donor heart in the setting of elevated recipient pulmonary vascular resistance is a specific early concern. Infection is a major risk throughout the post-transplant period due to lifelong immunosuppression; bacterial, fungal (particularly Aspergillus), and viral infections (especially cytomegalovirus) are common and require vigilant prophylaxis and monitoring.

Acute cellular rejection, mediated by T-cells, typically occurs in the first year and is monitored by serial endomyocardial biopsies. Antibody-mediated rejection, driven by donor-specific antibodies, is harder to treat and associated with worse outcomes. Cardiac allograft vasculopathy — an accelerated form of coronary artery disease affecting the donor heart — is the leading cause of death beyond the first year, occurring in up to 50% of recipients by 10 years on angiographic screening. Long-term immunosuppression also causes significant morbidity: hypertension (>90%), hyperlipidaemia (>80%), renal dysfunction (chronic kidney disease requiring dialysis in 5–10% at 10 years), new-onset diabetes, and post-transplant lymphoproliferative disorder (a form of lymphoma, 1–3% incidence). Calcineurin inhibitor nephrotoxicity is a leading cause of long-term morbidity and sometimes necessitates subsequent renal transplantation.

After discharge, recipients require frequent outpatient visits — typically weekly for the first three months, then monthly for the remainder of the first year, then every three to six months thereafter. Serial endomyocardial biopsies via a right heart catheter are performed — weekly to monthly in the first three to six months, then annually — to screen for acute rejection before clinical deterioration occurs. Coronary angiography or intravascular ultrasound (IVUS) is performed annually from year one to monitor for cardiac allograft vasculopathy. Full blood counts, renal and liver function, drug levels (tacrolimus trough), blood pressure, and lipids are monitored at every visit.

Patients must take immunosuppressive medications for life without interruption. After three to six months, most patients progress through a supervised cardiac rehabilitation programme aimed at restoring exercise capacity and cardiovascular conditioning. Activity restrictions are largely lifted at six to twelve months. Sun protection and regular skin cancer screening are essential as post-transplant patients have a 100-fold increased risk of squamous cell carcinoma of the skin. Annual vaccinations (inactivated vaccines only — live attenuated vaccines are contraindicated), dental hygiene, and avoidance of raw or undercooked food to reduce infection risk are important long-term lifestyle modifications.

Heart transplantation is among the most expensive surgical procedures globally, reflecting the complexity of donor organ procurement, surgical technique, multi-disciplinary team involvement, and intensive post-operative care. In the United States, the total cost for heart transplantation — including pre-transplant evaluation, surgery, hospitalisation, and the first year of follow-up — typically ranges from USD 1,000,000 to USD 1,500,000. In the United Kingdom, costs under the NHS are covered for eligible residents, but private patients face similar costs. In India, leading centres such as Fortis Malar (Chennai), Apollo Hospitals (Delhi/Hyderabad), and AIIMS Delhi perform heart transplants at a total cost of USD 50,000–100,000, representing savings of over 90% versus US prices.

In Thailand (Bumrungrad International, Bangkok Heart Hospital) costs range from USD 80,000–130,000, while Turkey (Ankara Bilkent City Hospital) offers transplants at approximately USD 60,000–90,000. The ongoing cost of immunosuppressive medications — approximately USD 15,000–30,000 per year in the US — is often manageable at USD 2,000–5,000 per year in India and other medical tourism destinations with generic drug availability. Patients considering international transplantation must ensure the centre has a dedicated transplant programme with an established ISHLT registry record, an experienced multidisciplinary transplant team, and long-term follow-up capability.

For patients who are not yet at transplant candidacy stage, guideline-directed medical therapy — including the four pillars of heart failure management (ACE inhibitor/ARNI, beta-blocker, MRA, SGLT2 inhibitor) — can substantially reduce mortality and hospitalisation. Cardiac resynchronisation therapy (CRT) with or without defibrillation improves ejection fraction and symptoms in patients with left bundle branch block. In selected patients with ischaemic cardiomyopathy, coronary revascularisation via bypass surgery or angioplasty can improve viable hibernating myocardium and cardiac function. For patients with end-stage heart failure who are not transplant candidates due to comorbidities, permanent LVAD implantation as destination therapy (rather than bridge to transplant) provides survival and quality-of-life benefits comparable to transplantation at one to two years, with a two-year survival of approximately 65–70% in current-generation devices.